



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Jacobsen, AV;Pierotti, CL;Lowes, KN;Au, AE;Zhang, Y;Etemadi, N;Fitzgibbon, C;Kersten, WJA;Samson, AL;van Delft, MF;Huang, DCS;Sabroux, HJ;Lessene, G;Silke, J;Murphy, JM

Title:

The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL

Date:

2022-04-01

Citation:

Jacobsen, A. V., Pierotti, C. L., Lowes, K. N., Au, A. E., Zhang, Y., Etemadi, N., Fitzgibbon, C., Kersten, W. J. A., Samson, A. L., van Delft, M. F., Huang, D. C. S., Sabroux, H. J., Lessene, G., Silke, J. & Murphy, J. M. (2022). The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL. *Cell Death and Disease*, 13 (4), <https://doi.org/10.1038/s41419-022-04740-w>.

Persistent Link:

<https://hdl.handle.net/11343/307199>

License:

[CC BY](#)

ARTICLE OPEN



The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL

Annette V. Jacobsen ^{1,2}, Catia L. Pierotti^{1,2}, Kym N. Lowes^{1,2}, Amanda E. Au^{1,2}, Ying Zhang^{1,2}, Nima Etemadi ¹, Cheree Fitzgibbon^{1,2}, Wilhelmus J. A. Kersten¹, André L. Samson ^{1,2}, Mark F. van Delft ^{1,2}, David C. S. Huang ^{1,2}, H el ene Jousset Sabroux^{1,2}, Guillaume Lessene ^{1,2,3}, John Silke ^{1,2} and James M. Murphy ^{1,2}

  The Author(s) 2022

Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein kinase (RIPK)-1 and RIPK3, within a complex known as the necrosome. Dysregulated necroptosis has been implicated in numerous inflammatory pathologies. As such, new small molecule necroptosis inhibitors are of great interest, particularly ones that operate downstream of MLKL activation, where the pathway is less well defined. To better understand the mechanisms involved in necroptosis downstream of MLKL activation, and potentially uncover new targets for inhibition, we screened known kinase inhibitors against an activated mouse MLKL mutant, leading us to identify the lymphocyte-specific protein tyrosine kinase (Lck) inhibitor AMG-47a as an inhibitor of necroptosis. We show that AMG-47a interacts with both RIPK1 and RIPK3, that its ability to protect from cell death is dependent on the strength of the necroptotic stimulus, and that it blocks necroptosis most effectively in human cells. Moreover, in human cell lines, we demonstrate that AMG-47a can protect against cell death caused by forced dimerisation of MLKL truncation mutants in the absence of any upstream signalling, validating that it targets a process downstream of MLKL activation. Surprisingly, however, we also found that the cell death driven by activated MLKL in this model was completely dependent on the presence of RIPK1, and to a lesser extent RIPK3, although it was not affected by known inhibitors of these kinases. Together, these results suggest an additional role for RIPK1, or the necrosome, in mediating human necroptosis after MLKL is phosphorylated by RIPK3 and provide further insight into reported differences in the progression of necroptosis between mouse and human cells.

Cell Death and Disease (2022)13:291 ; <https://doi.org/10.1038/s41419-022-04740-w>

INTRODUCTION

Necroptosis is a caspase-independent form of cell death that involves membrane disruption and the release of cytokines and damage-associated molecular patterns. In mammals, necroptosis appears to have evolved in conjunction with microbial pathogens, as there is evidence for a variety of bacterial and viral proteins that target the necroptosis pathway [1–5]. There is also increasing evidence implicating necroptosis in a range of inflammatory, autoimmune and neurodegenerative diseases (reviewed in [6, 7]) and cancers (reviewed in [8]). For these reasons, there has been much interest in the cell death community in developing inhibitors of necroptosis.

Necroptosis can be activated through engagement of several different extracellular receptors, including death receptors such as tumour necrosis factor receptor 1 (TNFR1), interferon receptors, and Toll-like receptors [9–13]. The pathway can be induced pharmacologically using death ligands such as TNF to engage TNFR1, Smac-mimetics to block the activity of the inhibitor of apoptosis protein (IAP) family of E3 ubiquitin ligases, and caspase inhibitors to prevent the activity of caspases, specifically caspase-8 (CASP8), whose proteolytic activities underlie apoptotic cell death

[14]. After engagement of the TNFR1 receptor with TNF, ubiquitylation of receptor interacting protein kinase (RIPK)-1 by cIAPs, which normally prevents cell death, is blocked by the Smac-mimetics. This allows RIPK1 to form a second complex in the cytoplasm that includes CASP8, typically leading to activation of CASP8 and cell death [15–17]. However, in the presence of caspase inhibitors, CASP8 cleavage of RIPK1 is prevented, allowing RIPK1 to associate with RIPK3 through their RIP homotypic interaction motifs (RHIMs) [14, 18–22]. This induces the autophosphorylation and activation of both kinases, allowing RIPK3 to recruit the pseudokinase, mixed lineage kinase domain-like (MLKL), the most downstream known obligate effector of the necroptosis pathway [23–25]. RIPK3 then phosphorylates the activation loop within MLKL’s pseudokinase domain, initiating a chain of events involving a conformational transition, oligomerisation and subsequent translocation of MLKL to cellular membranes, where membrane disruption mediated by MLKL’s N-terminal four-helix bundle (4HB) domain leads to death of the cell [25–36]. Several pathway interactors and modulators of necroptotic signalling have been identified [37–46], however the precise mechanism and regulation of MLKL-mediated plasma

¹The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. ²Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.

³Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, VIC, Australia. email: silke@wehi.edu.au; jamesm@wehi.edu.au

Received: 24 August 2020 Revised: 14 March 2022 Accepted: 16 March 2022

Published online: 01 April 2022




Fig. 1 **AMG-47a is a novel necroptosis inhibitor identified in mouse cells.** **A** AMG-47a was identified in parallel small molecule phenotypic screens to rescue cell death caused by TNF (100 ng/ml), Smac mimetic (0.5 μ M) and QVD-Oph (5 μ M) (TSQ) in wild-type murine dermal fibroblasts (MDFs), or by induction of MLKL^{Q343A} expression in *Mkl1*^{-/-} MDFs using doxycycline (dox; 1 μ g/ml) using a CellTiter Glow assay after 24 h treatment. Data are the mean of two technical replicates. **B** Wild-type MDFs were treated with AMG-47a (1 μ M) or an equivalent amount of DMSO, then challenged with TSQ or TSI (TNF (100 ng/ml), Smac mimetic (0.5 μ M), and caspase inhibitor IDN-6556 (emricasan; 5 μ M)) to induce necroptotic cell death or left untreated. After 6 h or 24 h PI uptake was measured using flow cytometry as above. Data were normalised to DMSO treated (0% cell death) and TSQ or TSI treated (100% cell death) and are shown as percentage rescue (see Supplementary Fig. 1A for raw data). **C–E** AMG-47a was assessed in murine RAW 264.7 and AML cell lines in 2-fold dilution series for both toxicity (AMG-47a alone), and its ability to protect against induction of necroptosis using TSI or, for murine AML cell lines, Smac mimetic and IDN-6556 alone (SI). Cell death was assessed 24 h after treatment by measuring propidium iodide (PI; 1 μ g/ml) uptake using flow cytometry, with a minimum of 5000 cells counted. Data represent three (**C**), seven (**D**) or four (**E**) independent biological replicates, and lines represent the mean (**C**) or individual replicates (**D**, **E**).

membrane disruption is less clear, with endosomal sorting complex proteins, flotillins, phosphatidylinositol phosphates, and ion channels all proposed to have important roles [27–29, 47–52]. Additionally, although there are many similarities between necroptotic signalling in human and mouse cells, key differences have also been shown, particularly in relation to how MLKL is activated by RIPK3 and the nature of the oligomeric complex formed after phosphorylation [30, 31, 33, 53, 54]. This incomplete understanding of the necroptotic signalling pathway poses a challenge to efforts to develop therapeutics.

To unravel some of these outstanding questions, we performed complementary phenotypic screens to identify small molecules that could block necroptosis downstream of MLKL activation, with a view to identifying previously unknown signalling molecules in the pathway. Using this strategy, we previously identified the chaperone, heat shock protein 90 (HSP90), as an MLKL interacting partner [39], a finding supported by two other independent research groups [55, 56]. Here, we describe our identification of the lymphocyte-specific protein tyrosine kinase (Lck) inhibitor, AMG-47a, as an inhibitor of necroptosis via its binding to the two key necroptotic effector kinases, RIPK1 and RIPK3. Surprisingly, while these data implicate RIPK1 as a target of AMG-47a, we also observed that AMG-47a inhibited necroptosis downstream of MLKL activation. Subsequent investigation revealed that death induced by dimerisation of the human MLKL N-terminal domain or overexpression of human RIPK3 is dependent on the presence of RIPK1. Collectively, these data implicate an additional role of RIPK1 in necroptosis downstream of MLKL activation.

RESULTS

AMG-47a inhibits necroptosis in a stimulus-dependent manner

To identify novel inhibitors of necroptosis at the level of, or downstream of, MLKL activation, we used two independent phenotypic screens against a library of known kinase inhibitors, as

described previously [39]. In the first screen, wild-type murine dermal fibroblasts (MDFs) were treated with a combination of small molecules known to induce necroptosis (TNF; the Smac-mimetic, Compound A; and the caspase inhibitor QVD-Oph; TSQ). In the second screen, *Mkl1*^{-/-} MDFs inducibly-expressing the auto-activating MLKL^{Q343A}, were used [25]. From this screen, we found the lymphocyte-specific kinase (Lck) inhibitor, AMG-47a [57], restricted MLKL-dependent cell death in both cell lines (Fig. 1A). To independently validate this, we assessed the ability of AMG-47a to protect against necroptotic cell death induced by either TSQ or TSI (I: the caspase inhibitor IDN-6556) in wild-type MDFs (Fig. 1B). We found that AMG-47a was able to protect against TSQ-mediated cell death and, although there was some variability in the response, this was statistically significant at 6 h (Supplementary Fig. 1A). However, there was less protection against TSI-induced cell death, known to be a stronger inducer of necroptosis [58], even at early time points.

We then assessed whether AMG-47a could protect other murine cell lines shown to die by necroptosis [58, 59]. AMG-47a inhibited TSI-induced necroptosis of RAW cells at a concentration of 0.25–0.5 μ M, however toxicity was also observed in cells treated with AMG-47a at doses greater than 1 μ M (Fig. 1C). We saw similar protection from necroptotic cell death induced by SI in HoxA9-Meis1 AML cells between 125 nM and 1 μ M (Fig. 1D, Supplementary Fig. 1B). In contrast, AMG-47a provided little protection against the same necroptotic stimulus in MLL-AF9, MLL-AF9-NRas and MLL-ENL AML cells (Fig. 1E, Supplementary Fig. 1C–E). To understand the variation between the different murine AML cell lines, we examined the expression of necroptosis effectors in HoxA9-Meis1 and MLL-AF9 AML cell lines. Interestingly, both RIPK1 and MLKL were expressed at much lower levels in HoxA9-Meis1 cells (Supplementary Fig. 1F), which were the most responsive to AMG-47a inhibition (Fig. 1D).

To address the identified toxicity, we examined whether genetic deletion of key components of different cell death pathways in




Fig. 2 AMG-47a toxicity is Bax/Bak dependent. **A** MDFs and MEFs of various genotypes were treated with increasing doses of AMG-47a, or DMSO alone. After 24 h, cells were harvested and assessed for PI uptake via flow cytometry, with a minimum of 5000 cells counted. Results represent four independent experiments for MDF cell lines and *Ripk1*^{-/-} MEFs, and five independent experiments for all other MEF cell lines. **B** Samples of untreated MDFs or MEFs of each genotype used in **(A)** were collected, lysed, and analysed via western blotting to confirm cells of the correct genotype were being used. Data shown are representative of two individual experiments done at different time points over the course of the toxicity experiments.

MDFs or murine embryonic fibroblasts (MEFs) led to protection upon treatment with increasing doses of AMG-47a (Fig. 2A, B). Only *Bax*^{-/-}*Bak*^{-/-} MEFs were completely protected from AMG-47a mediated toxicity (Fig. 2A), suggesting that the compound was initiating apoptosis at higher doses.

We then investigated the ability of AMG-47a to inhibit necroptosis in a range of human cell lines at both 24 and 48 h (Fig. 3A–F, Supplementary Fig. 2A–D). We found that AMG-47a provided robust protection from both TSQ and TSI-induced cell death in U937 histiocytic lymphoma, HT29 colorectal adenocarcinoma and THP-1 acute monocytic leukaemia cells, with IC₅₀ values ranging from ~100 nM to ~2.5 μM (Table 1), showing protection comparable to known RIPK1, RIPK3 and MLKL inhibitors (Supplementary Fig. 2E–M). Notably, as in MDFs (Fig. 1B), in U937 and HT29 we found higher doses of AMG-47a were required to block TSI-induced cell death. Also similar to mouse cell lines, we noted some toxicity at higher doses in human cell lines; this was most noticeable in THP-1 cells treated for 24 h with concentrations of AMG-47a above 1 μM (Fig. 3E). Finally, to determine whether the observed protection was specific to the necroptotic pathway, we treated U937 and HT29 cells with the apoptotic stimulus of TNF and Smac-mimetic (TS) ± AMG-47a. Although AMG-47a slightly reduced apoptotic death of U937 cells at lower concentrations,

this protection was not observed in the dose range required to block necroptosis, and it had no effect on apoptotic death of HT29 cells (Supplementary Fig. 3N, O). Together, these experiments indicate that cells stimulated with less potent necroptotic stimuli and/or those expressing necroptosis effectors at lower abundance are more amenable to AMG-47a protection.

AMG-47a inhibits necroptosis downstream of MLKL activation

As we had observed that AMG-47a was more effective at blocking necroptosis in human cells, and because human and mouse MLKL have mechanistic differences in the way they kill cells [30, 31, 33, 54, 60, 61], we focused on how AMG-47a inhibited necroptosis at, or downstream of, MLKL activation in human cells. We therefore generated U937 cells that inducibly-expressed regions of the N-terminal killer domain of human MLKL fused to a C-terminal gyrase B domain, which can be forced to dimerise on addition of the bivalent antibiotic coumermycin [62]. In our hands, this is the only system that we have found to induce MLKL-dependent cell death independent of activation of upstream signalling in human cells [30, 31]. We initially tested a human MLKL^(1–180) fusion, expressing the full N-terminal domain (NTD) consisting of the four-helix bundle (4HB) and neighbouring two-helix “brace region” of the protein. The dimerised NTD-gyrase




Fig. 3 AMG-47a is a strong necroptosis inhibitor in human cell lines. **A–F** AMG-47a was assessed in human U937, HT29 and THP-1 cell lines in 2-fold dilution series for both toxicity (AMG-47a alone), and its ability to protect against induction of necroptosis using TSI. Cell death was assessed 24 h (**A, C, E**) or 48 h (**B, D, F**) after treatment by measuring propidium iodide (PI; 1 $\mu\text{g}/\text{ml}$) uptake using flow cytometry, with a minimum of 5000 cells counted. Data represent three (**A, B, E, F**) or four (**B, D**) independent biological replicates, and lines represent the mean.

Table 1. IC_{50} values of AMG-47a in human cell lines.

Cell line	Necroptotic stimulus	Time (h)	IC_{50} (μM)	95% CI (μM)
U937	TSQ	24	0.29	0.11 to 0.80
		48	0.11	0.07 to 0.18
	TSI	24	1.13	0.67 to 2.03
		48	1.62	0.55 to 5.97
HT29	TSQ	24	0.12	0.03 to 0.32
		48	0.51	0.18 to 1.78
	TSI	24	0.38	0.10 to 1.56
		48	2.44	1.12 to 6.00
THP-1	TSI	24	0.15	0.04 to 0.45
		48	0.32	0.12 to 0.92

IC_{50} values were calculated from a minimum of 3 independent experiments and are derived from the data presented in Fig. 3 and Supplementary Fig. 2A–D.

construct induced cell death in wild-type U937 cells, as previously reported [30], and also, albeit to a slightly lesser extent, in $\text{MLKL}^{-/-}$, $\text{RIPK3}^{-/-}$, and $\text{BAX}^{-/-}\text{BAK}^{-/-}$ cells (Fig. 4A–C). IncuCyte imaging of the $\text{MLKL}^{-/-}$ cells expressing this construct confirmed that cells exhibited swelling synonymous with necroptotic cell death during induction which, importantly, could be blocked by treatment with necrosulfonamide (NSA [23]) (Fig. 4D). Surprisingly, this construct was completely unable to kill cells when expressed in $\text{RIPK1}^{-/-}$ U937 cells, even when induced and dimerised over 48 h (Fig. 4B), despite the fusion protein being expressed similarly in all cell lines (Fig. 4C). Furthermore, the brace region of human MLKL contributed to the toxicity of this construct, because a fusion protein without the brace and consisting only of the 4HB domain ($\text{MLKL}^{(1-125)}$) could not induce cell death in the absence of endogenous MLKL (Supplementary Fig. 3A).

To test this further, we used another independent system to directly activate MLKL by inducibly expressing human RIPK3 in wild-type U937 cells. To overcome the propensity of RIPK3 to induce apoptosis when overexpressed [63, 64], a caspase inhibitor must be added simultaneously with RIPK3 induction to induce necroptotic cell death. Consistent with these published data, cell death induced by RIPK3 was only blocked by NSA in the presence of a caspase inhibitor (Fig. 4E). Remarkably, inducible RIPK3 necroptosis was also dependent on RIPK1 (Fig. 4F), since $\text{RIPK1}^{-/-}$ cells were resistant to RIPK3 induced death, although this death

could not be blocked by the RIPK1 kinase inhibitors, Nec-1s and GSK-481, or the RIPK3 kinase inhibitors, GSK-843 and GSK-872 (Fig. 4E).

Having established MLKL-dependent cell death assays, we used three different protocols to examine whether AMG-47a could block death induced by expression and dimerisation of the NTD-gyrase constructs in U937 (Fig. 5A). In the first protocol, we treated cells with AMG-47a, other known cell death inhibitors, or DMSO, then added doxycycline and coumermycin 1 h later. This protocol promotes dimerisation and activation of the fusion proteins as they are expressed and provides AMG-47a with a long window of action. In the second protocol, we also added AMG-47a prior to induction of expression, but we substantially delayed addition of coumermycin. This allowed levels of the fusion protein to accumulate prior to dimerisation, which, we hypothesised would be a stronger, acute cell death stimulus for AMG-47a to inhibit. Finally, in the third protocol, we expressed the protein overnight in the absence of inhibitors, adding either inhibitor (or DMSO) just prior to addition of coumermycin to determine whether any inhibitory effects were related to the dimerisation step. Importantly, in all protocols cell death was nearly completely blocked by NSA, confirming that in each case the cell death was MLKL-dependent (Fig. 5B, Supplementary Fig. 3B–D). For all experiments, inhibitors were used at doses that were non-toxic for the duration of the experiment (Supplementary Fig. 3E). Based on previous




Fig. 4 RIPK1 impacts cell death downstream of MLKL activation. **A, B** U937 cell lines of various genotypes expressing an inducible MLKL(1-180)-gyrase fusion were treated with doxycycline (to induce expression) and/or coumermycin (to induce dimerisation), or left untreated. After 24 h (**A**) or 48 h (**B**), cells were harvested and assessed for cell death (PI uptake measured using flow cytometry), counting a minimum of 5000 cells. Data represent three independent experiments, with the exception of the *BAX*^{-/-}*BAK*^{-/-} cell lines, where *n* = 2. Statistics were calculated in GraphPad Prism 8, and *p* values are shown where <0.05. **C** The same U937 cells used in panel A and B were treated with doxycycline alone and left overnight. After approximately 16 h, cells were harvested and lysed for analysis of fusion protein expression via western blot. The upper MLKL band (*) represents endogenous MLKL, and the lower band (arrow) represents the MLKL⁽¹⁻¹⁸⁰⁾-gyrase fusion protein. **D** Wild-type U937 were treated with TNF (100 ng/ml), Smac-mimetic (0.5 μM), and caspase inhibitor IDN-6556 (emricasan; 5 μM) (TSI) to induce necroptosis or TNF and Smac-mimetic (TS) alone to induce apoptosis. In parallel, *MLKL*^{-/-} U937 expressing an inducible MLKL⁽¹⁻¹⁸⁰⁾-gyrase fusion were treated with doxycycline and coumermycin in the presence or absence of necrosulfonamide (NSA). Images were taken at the specified timepoints using an IncuCyte S3 System to track morphological changes and PI uptake (shown by red). Cells with a necroptotic phenotype (cellular swelling) are indicated with yellow arrows. Three fields were examined per well with representative data shown. **E** Wild-type U937 cells were treated with doxycycline (20 nM) to induce expression of human wild-type RIPK3 in the presence of various cell death inhibitors, as indicated, for 24 h. At the conclusion of the experiment, cells were analysed for PI uptake using flow cytometry, with a minimum of 5000 cells counted. Data represent four or more independent experiments. **F** Wild-type, *MLKL*^{-/-} and *RIPK1*^{-/-} U937 expressing inducible human wild-type RIPK3 were treated with doxycycline (20 nM) and IDN-6556 (5 μM), doxycycline alone, or left untreated. After 24 h, cell death was measured as PI uptake using flow cytometry. Data are a summary of six independent experiments.

reports that low levels of activated MLKL can be turned over [48, 49, 51, 65, 66], we had anticipated that a slow build-up of active MLKL (protocol 1) might be less toxic to cells than protocol 2. However, we did not observe such a difference (Fig. 5B). Consistent with this, using either protocol 1 or 2, we observed that AMG-47a inhibited cell death in wild-type U937 cell lines expressing the NTD-gyrase fusion protein, although AMG-47a did not block cell death as efficiently as pretreatment with NSA (Fig. 5B). Similarly, pretreatment with AMG-47a reduced cell death when the NTD-gyrase fusion was dimerised in *MLKL*^{-/-}, *RIPK3*^{-/-} or *BAX*^{-/-}*BAK*^{-/-} U937 cells (Supplementary Fig. 3B–D). However, when we delayed the addition of AMG-47a (protocol 3) we found it was no longer able to protect against cell death in any of the genotypes tested, although NSA was still able to provide near complete protection (Fig. 5B, Supplementary Fig. 3B, C). We did not observe any protection, in any of the genotypes or protocols, when cells were pretreated with the RIPK1 kinase inhibitor Nec-1s or the RIPK3 kinase inhibitor GSK-872, either as a single agent or in combination, with the exception of a small but significant difference when the combination was used in *BAX*^{-/-}*BAK*^{-/-} U937 cells (Fig. 5B, Supplementary Fig. 3B–D). We also observed

some protection from caspase inhibitors alone in both *MLKL*^{-/-} and *RIPK3*^{-/-} U937 cells (Supplementary Fig. 3B, C).

Finally, we assessed the ability of AMG-47a to protect against cell death caused by inducible expression of human RIPK3. In this assay, AMG-47a was protective at doses greater than 400 nM, although, as before, AMG-47a was toxic at 30 μM, the highest dose tested (Fig. 5C). Together, these results support the idea that AMG-47a can inhibit MLKL-induced necroptotic cell death, particularly following treatment with less severe necroptotic stimuli. Furthermore, they suggest that, in human cells, the NTD of MLKL requires RIPK1 to kill, and that AMG-47a can inhibit necroptosis downstream of MLKL activation.

AMG-47a is a dual RIPK1/RIPK3 inhibitor

Based on the above results, we hypothesised that following a classic necroptotic stimulus AMG-47a might operate both upstream and downstream of MLKL activation. To test this idea, we performed a time-course to examine phosphorylation of RIPK1, RIPK3, and MLKL in the human U937 and HT29 cell lines undergoing necroptosis in the absence or presence of AMG-47a. In both U937 and HT29 cells, we saw a marked reduction of MLKL




Fig. 5 AMG-47a inhibits necroptosis downstream of MLKL activation. **A** Three different experimental protocols were used to assess the ability of AMG-47a to inhibit cell death caused by the expression and dimerisation of the MLKL⁽¹⁻¹⁸⁰⁾-gyrase fusion protein. In protocol 1, inhibitors (or DMSO) were added first, followed by doxycycline and coumermycin together, so that the fusion protein could dimerise on expression. In protocol 2, addition of coumermycin was delayed to allow levels of the fusion protein to accumulate before dimerisation was induced. In protocol 3, the addition of inhibitors (or DMSO) was also delayed, so that it was added after the fusion protein had been expressed for 16 h, but before the addition of coumermycin. In all experimental methods, cells were harvested 24 h after the experiment was initiated. **B** Wild-type U937 cells expressing the MLKL⁽¹⁻¹⁸⁰⁾-gyrase fusion protein were treated using either protocol 1, 2, or 3, as described above (**A**). At the conclusion of the experiment, cells were analysed for PI uptake using flow cytometry, with a minimum of 5000 cells counted. Data represent three independent experiments; bars indicate the mean and error bars indicate standard error of the mean. Statistics were calculated in GraphPad Prism8, and *p* values are shown where <0.05. **C** Wild-type U937 cells with inducible human RIPK3 were treated with increasing doses of AMG-47a in the presence of 40 nM doxycycline, to induce expression, and 5 μM IDN-6556, to block caspase-dependent cell death. After 48 h, cells were harvested and viability assessed using the Cell-Titer Glo 2 (Promega) system. Data represent two independent experiments (four replicates per experiment) and have been normalised against doxycycline plus IDN-6556 (0% viability) and doxycycline plus IDN-6556 plus NSA (100% viability).

phosphorylation when cell lines were pretreated with AMG-47a, as well as a delay in both RIPK1 and RIPK3 phosphorylation in U937 cells, however inhibition of RIPK1 and RIPK3 phosphorylation by AMG-47a was less pronounced in HT29 cells (Fig. 6A, B). Additionally, we observed delayed RIPK1 phosphorylation in MDFs pretreated with AMG-47a, as well as a reduction in both RIPK3 and MLKL phosphorylation (Fig. 6C). To determine whether AMG-47a was interacting with these proteins in a cellular context, we performed cellular thermal shift assays (CETSA [67]) in both U937 and MDF cell lines. In both cell lines we found incubation with AMG-47a increased the stability of RIPK1 to a similar or greater extent than known RIPK1 inhibitors GSK-481 and Nec-1s, suggesting that AMG-47a binds to RIPK1 in cells (Fig. 6D, E). However, neither RIPK3 nor MLKL stability was affected by the presence of AMG-47a in either cell line, suggesting that they are not direct targets of AMG-47a in cells.

To better understand the nature of these interactions, we determined the K_d of the interaction between AMG-47a and the necroptotic effector proteins using the DiscoverX competitive kinase binding assay [68]. We found that AMG-47a bound to both RIPK1 (K_d 199 nM; 95% CI 154–258 nM; Fig. 6F, Supplementary Fig. 4A–D) and RIPK3 (K_d 209 nM; 95% CI 85–508 nM; Fig. 6G, Supplementary Fig. 4E, F), confirming that AMG-47a could influence their ability to bind ATP. As described previously [57], we also found AMG-47a bound VEGFR2, with 50% binding observed at 50 nM and over 90% binding at 500 nM. In contrast, no binding to human MLKL was detected at 12 μM , the maximum dose tested. Finally, we assessed whether AMG-47a binding affected RIPK1 and RIPK3 kinase activity. We found that AMG-47a was able to inhibit both RIPK1 and RIPK3 kinase activity in enzymatic assays, with IC_{50} values of 83 nM (95% CI 59–115 nM) and 13 nM (95% CI 10–16 nM), respectively (Fig. 6H, I). Together, these results indicate that AMG-47a inhibits MLKL induced necroptosis by targeting a RIPK1/MLKL function in cells and inhibits the kinase activity of both RIPK1 and RIPK3.

DISCUSSION

In this study, we identified AMG-47a as an inhibitor of necroptosis. While it functioned to block necroptosis induced by activated forms of MLKL, such as the Q343A mouse MLKL mutant and dimerised human MLKL NTD, we were unable to find evidence that it interacts directly with MLKL. Instead, our data indicate that AMG-47a interacts with both RIPK1 and RIPK3 to inhibit necroptosis. Together with our genetic data, this strongly suggests that constitutively-activated forms of human MLKL rely on RIPK1 and, to a lesser extent, RIPK3 for their full cytotoxic activity. Notably, while AMG-47a competed with ATP binding to both RIPK1 and RIPK3 and inhibited their kinase activity in vitro, other documented inhibitors of these kinases did not prevent activated MLKL killing. Therefore, the role of RIPK1 and RIPK3 in activated MLKL killing appears to be independent of their kinase activity. These data substantially revise our understanding of necroptosis as a linear pathway and expose the limitations of classic genetic approaches as a means to understand such pathways. Thus, if RIPK1 is required both upstream and downstream of MLKL activation, only the epistatic upstream effects would be revealed by genetic deletion of these effectors. Such an interpretation of our results fits with recent findings that suggest a combination of regulators determines whether cells undergo necroptosis or apoptosis rather than a simple linear pathway [20–22].

AMG-47a was identified as an Lck inhibitor, which inhibited IL-2 production in human and mouse cells [57]. However, binding of AMG-47a to Lck is unlikely to contribute towards its protective effects against necroptosis found here, as Lck expression is known to be very low in HT29 cells [69, 70]. In addition to binding of Lck, AMG-47a was also found to bind kinases involved in cell death pathways, including MAPKs, such as p38 α , at low nanomolar concentrations and JNK1–3 at mid nanomolar concentrations, with AMG-47a shown to reduce ERK1/2 phosphorylation in A375 human melanoma cells [71]. However, we only observed a limited capacity of AMG-47a to block extrinsic apoptosis. In the subset of




Fig. 7 Model for a role of RIPK1 in necroptosis downstream of MLKL activation. A The cell death induced by forced dimerisation of the human MLKL NTD involves two distinct processes. In the first, MLKL can self-associate into discrete oligomers on addition of doxycycline. In the second, addition of coumermycin promotes the assembly of large multimeric complexes. AMG-47a is unable to inhibit the second process, thus we propose it prevents membrane attachment, translocation, or oligomerisation of the human MLKL NTD through its activity as a kinase inhibitor. As AMG-47a binds RIPK1, and as RIPK1 is required for this form of cell death, we propose the primary target of AMG-47a is RIPK1 in this context. **B** When a cell receives a necroptotic stimulus, a number of key events occur, beginning with assembly of a necrosome containing RIPK1, RIPK3, and MLKL. This triggers a number of events, beginning with the phosphorylation of MLKL by RIPK3, which enables a conformational change in MLKL that allows oligomerisation, translocation to cellular membranes, and ultimately cell death. Our data suggest an additional role for RIPK1 in human necroptosis by supporting the conformational change, oligomerisation, or membrane translocation of MLKL following phosphorylation by RIPK3.

This simple mechanism does not translate to human cells because phosphomimetic mutants of MLKL, or expression of the NTD alone, are inadequate to kill human cells [30, 31]. However, stimulus independent cell death can be induced in human cells when the N-terminal regions of human MLKL are fused to a dimerisation domain [30], supporting the idea that there are additional regulatory processes between phosphorylation of MLKL and cell death in the human necroptotic pathway that are not present in mouse cells. Unexpectedly, we found that death mediated by forced dimerisation of the human MLKL NTD was completely dependent on the presence of the upstream necroptotic effector protein, RIPK1, and to a lesser extent on RIPK3. These findings, combined with recent data showing RIPK1 co-localises with MLKL after phosphorylation in human HT29 cells [32], suggest that a prolonged association with necrosome components is important for progression of necroptosis after MLKL is phosphorylated by RIPK3 in human cells. The extent to which human cell lines more broadly rely on RIPK1 downstream of MLKL NTD forced dimerization for cell death remains the subject of ongoing interest. Further interrogation of the role of RIPK1 downstream of MLKL activation awaits the generation of necroptosis-competent cell lines, such as THP1 [73] or Molt4 [32], in which *RIPK1*, *RIPK3* or *MLKL* have been knocked out.

Interestingly, our finding that RIPK1 was a target of AMG-47a suggests that it may block NTD-tyrosine-mediated cell death through either direct or indirect interaction with RIPK1. Because the known RIPK1 kinase inhibitor, Nec-1s, was unable to block NTD-tyrosine-mediated cell death, this suggests that RIPK1 likely plays a scaffolding role, such as nucleating assembly of necrosomes in the cytoplasm, as platforms for activation of the downstream effectors, RIPK3 and MLKL. Further validation of the kinase-independent role of RIPK1 downstream of MLKL activation awaits future generation of necroptosis-competent cell lines expressing kinase-dead mutant RIPK1. Although RIPK1 has an

established role as an important apical component in necroptotic signalling, studies in mouse cells highlight a more complex involvement of RIPK1, including restricting necroptosis in particular contexts, especially during development [74–77]. Additionally, there have also been a number of reports indicating that necroptosis can proceed in the absence of RIPK1 in mouse cells [78–80], particularly in the case of interferon signalling, where the RHIM-containing protein ZBP-1/DAI was proposed to interact with RIPK3 to induce necroptosis [81, 82]; whether this holds true in human cell necroptosis has not been investigated. Our findings indicate the involvement of RIPK1 in the progression of necroptosis may not be analogous between species and indicates an obligate role downstream of MLKL activation in human cells. This is supported by our finding that death caused by human RIPK3 overexpression was also reliant on the presence of RIPK1. This contrasts previous findings in mouse cell lines, where RIPK3 overexpression could induce TNF-dependent necroptosis in the absence of RIPK1 [78]. Interestingly, like the NTD-tyrosine experiments, killing induced by human RIPK3 overexpression could not be blocked by established RIPK1 kinase inhibitors, but could be inhibited by AMG-47a, suggesting a similar mechanism for RIPK1 may be involved in both contexts. Notably, both Nec-1s and GSK-481 are classified as Type III inhibitors and bind the same allosteric region of RIPK1 overlapping the ATP binding site [83], whereas AMG-47a is a Type II inhibitor and bind within the ATP binding site of Lck [57]. It is possible that these differences in binding mode could lead to structural differences in RIPK1 which may change how RIPK1 interacts with MLKL in the presence of different inhibitors.

The data reported herein have enabled us to propose a revised model of human necroptotic signalling downstream of MLKL activation (Fig. 7). Our NTD-tyrosine experiments suggest two distinct processes: assembly of the MLKL NTD into discrete oligomers, likely through interactions mediated by the brace

region of the NTD; and addition of coumermycin acts to link the MLKL oligomers into large multimeric complexes that can destabilise cell membranes and induce cell death (Fig. 7A). Our data suggest that AMG-47a prevents cell death mediated by forced dimerisation of the human MLKL NTD by inhibiting the formation of the MLKL NTD into discrete oligomers, and/or by inhibiting the translocation of these oligomers to cell membranes. This mechanism of action contrasts the MLKL NTD inhibitor, NSA, which was able to block cell death when introduced both before expression and before dimerisation. These results, together with the reliance of human MLKL NTD-gyrase and human RIPK3 overexpression on RIPK1 for necroptotic signalling, indicate that, in the context of the human necroptotic pathway, RIPK1 may have an additional role in activating the MLKL NTD when disengaged from the pseudokinase domain post-phosphorylation (Fig. 7B). Whether this supports the conformational change of MLKL post-phosphorylation, mediates MLKL oligomerisation, or facilitates translocation of MLKL to cellular membranes is yet to be determined. A dual role of RIPK1 at the apex of the human necroptosis pathway and downstream of RIPK3/MLKL activation, as identified here, helps provide further insight into the mechanistic differences in necroptosis signalling that occur downstream of MLKL phosphorylation in mouse and human cells.

MATERIALS AND METHODS

Antibodies, chemicals, and reagents

The following primary antibodies were used in this study: rat anti-MLKL clone 3H1 (available as MABC604 from Merck Millipore; 1:1000) was produced in-house as previously described [25]; rabbit anti-human MLKL pS358 (ab187091, Abcam, Cambridge, United Kingdom; 1:4000); rabbit anti-mouse MLKL pS345 (ab196436, Abcam; 1:1000); rat anti-human RIPK3 (clone 1H2; available as MABC1640 from Merck Millipore; 1:1000) and rat anti-mouse RIPK3 (clone 8G7; available as MABC1595 from Merck Millipore; 1:1000) produced in-house as previously described [3, 84]; rabbit anti-RIPK3 (2283, ProSci; 1:1000); rabbit anti-human RIPK3 pS227 (ab209384, Abcam; 1:2000); rabbit anti-mouse RIPK3 pT231/pS232 (GEN135-35-9, kindly supplied by Genentech, South San Francisco, CA, USA [74]; 1:2000); mouse anti-RIPK1 (610458, BD Transduction Laboratories, San Jose, CA, USA; 1:1000); rabbit anti-RIPK1 (3493, Cell Signalling Technology, Danvers, MA, USA; 1:1000); rabbit anti-human RIPK1 pS166 (65746, Cell Signalling Technology; 1:1000); rabbit anti-mouse RIPK1 pS166 (31122, Cell Signalling Technology; 1:1000); rabbit anti-mouse CASP8 (4927, Cell Signalling Technology; 1:1000); rabbit anti-BAX (2772, Cell Signalling Technology; 1:1000); rabbit anti-BAX (06-536, Upstate Biotechnology, Lake Placid, NY, USA; 1:1000); rabbit anti-GAPDH (2118, Cell Signalling Technology; 1:1000); and mouse anti- β -Actin (A1978, Sigma-Aldrich; 1:3000). Polyclonal goat anti-mouse (1010-50), anti-rabbit (4010-05), and anti-rat (3010-50) HRP-conjugated secondary antibodies were all used at 1:5000 (SouthernBiotech, Birmingham, AL, USA). For Cellular Thermal Shift Assay (CETSA) experiments, chicken anti- β -actin-HRP (Santa Cruz Biotechnology, cat #sc-47778 HRP) was also used at 1:5000.

The following chemicals and biological reagents were used in this study: pan-caspase inhibitor QVD-OPH (HY-12305, MedChemExpress, Monmouth Junction, NJ, USA); Necrostatin-1s (Nec-1s; Calbiochem 504297, Merck Millipore, Darmstadt, Germany); GSK-481 (made by SYNthesis MedChem, Parkville, Australia); GSK-843 (SYN-5482, SYNkinase, Parkville, Australia); GSK-872 (SYN-5481, SYNkinase); and necrosulfonamide (NSA; 480073, Merck Millipore). AMG-47a for the phenotypic screen was produced by Compounds Australia, and for all other experiments, AMG-47a used was purchased through SYNkinase (SYN-1007) or MedChemExpress (HY-18303); all behaved analogously in side-by-side assays. The Smac-mimetic, Compound A [85], and pan-caspase inhibitor IDN-6556/emricasan were supplied by TetraLogic Pharmaceuticals. Human recombinant IL-3 was purchased from R&D Systems (203-IL, Minneapolis, MN, USA), and human recombinant TNF (hTNF-Fc) was produced in-house as previously described [86].

Phenotypic screen

A library of 276 kinase inhibitors with known targets was used for a phenotypic screen as previously described [39]. In brief, wild-type or *Mlkl*^{-/-} murine dermal fibroblasts (MDFs) expressing inducible MLKL^{Q343A}

were seeded into 384-well plates pre-prepared with the compounds at 1 μ M by Compounds Australia (Nathan, Australia) at 2000 cells/well. After 2 h pre-incubation with compounds, cell death was induced by addition of TNF (100 ng/mL), Smac-mimetic (0.5 μ M) and QVD-OPH (5 μ M) (TSQ) in the case of wild-type MDFs, and by addition of 1 μ g/ml doxycycline to induce expression of MLKL^{Q343A} in *Mlkl*^{-/-} MDFs. Cell viability was determined using the CellTiter-Glo[®] Luminescent Cell Viability Assay (Promega, Madison, WI, USA) after 24 h of treatment and normalised to DMSO-treated controls (100% viability) and TSQ/doxycycline only controls (0% viability).

Cell culture and AMG-47a titrations

Human histiocytic lymphoma U937 and human acute monocytic leukaemia THP-1 cell lines (ATCC) were cultured in RPMI media (produced in-house) supplemented with 8–10% foetal calf serum (FCS; Sigma-Aldrich). Murine acute myeloid leukaemia (AML) cell lines were cultured in Iscove's modified Dulbecco medium (IMDM; in-house) with 10% FCS and additional IL-3 (3 ng/ml). MLL-AF9, MLL-AF9-Ras, MLL-ENL and HoxA9-Meis1 AMLs were generated as previously described using retroviral constructs [58, 59]. For cell death assays, cells were seeded into 96-well plates at 5×10^4 cells/well and treated with increasing concentrations of AMG-47a (as stated in legends), or 0.5% v/v DMSO (Sigma-Aldrich) in control wells. After 2 h, cell death was induced in U937 and THP-1 using TNF (100 ng/ml), Smac-mimetic (0.5 μ M) and a caspase inhibitor (QVD-OPH at 10 μ M or IDN-6556 at 5 μ M) (TSQ/TSI); for murine AML lines, Smac mimetic and IDN-6556 (SI) were used alone to induce cell death, at the same concentrations as above. After a further 24 h, cell death was assessed by measuring % propidium iodide (PI; 1 μ g/ml) uptake using flow cytometry, counting a minimum of 5000 cells.

Human colorectal adenocarcinoma HT29 (ATCC), murine RAW 264.7 macrophage (ATCC), mouse embryonic fibroblast (MEF) and MDF cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; in-house) with additional FCS (8–10%). MDFs were generated from the dermis of wild-type, *Mlkl*^{-/-}, *Ripk3*^{-/-}, and *Casp8*^{-/-}*Mlkl*^{-/-} mice and immortalised as previously described [25, 87–89]. *Ripk1*^{-/-}*Mlkl*^{-/-} MDF cell lines generated for this study were harvested from the dermis of *Ripk1*^{-/-}*Mlkl*^{-/-} P1 mice, which have been described previously [75], and were immortalised using SV40 large T antigen-expressing lentivirus using analogous methods. Wild-type and *Bax*^{-/-}*Bak*^{-/-} MEFs were a gift from Grant Dewson and produced as previously described [90, 91]. *Ripk1*^{-/-} MEFs were generated from E13.5 embryos [92]. For cell death assays, MDFs/MEFs and HT29 cells were seeded into 48-well plates at 2.5×10^4 or 5×10^4 cells/well respectively, and RAW cells were seeded into 24-well plates at 5×10^4 cells/well. After one (MDF, MEF and RAW cells) or two (HT-29) nights for settling, cells were treated with AMG-47a or DMSO, then stimulated for cell death after 2 h with TSQ or TSI, and assessed for PI uptake using flow cytometry after a further 24 h, as described for above cell lines.

Cell death assays using constitutively-activated MLKL variants

U937 cells stably transduced with MLKL expression constructs were cultured in RPMI media as described above, with the addition of 2 μ g/ml puromycin to maintain selection of cells containing the transgene. For these experiments, we used previously-described human MLKL⁽¹⁻¹⁵⁶⁾- or MLKL⁽¹⁻¹⁸⁰⁾-gyrase fusion constructs [30], although the cell lines used in this study were newly generated. Expression was induced using doxycycline (20 ng/mL), and dimerisation was induced using the divalent antibiotic coumermycin (700 nM). Inhibitors, where used, were at the following concentrations: AMG-47a, 1 μ M; QVD-OPH, 10 μ M; IDN-6556, 5 μ M; Nec-1s, 5 μ M; GSK-872, 20 μ M; NSA, 1 μ M. All experiments were conducted in 96-well plates seeded at a cell density of 5×10^4 cells/well, and cell death was assessed at the end of the experiment (24 h or 48 h) as %PI uptake using flow cytometry, as described above.

Western blot analyses

For each experiment, 1×10^6 cells were lysed in 100 μ L of 2 \times Laemmli buffer (4% w/v SDS, 20% v/v glycerol, 120 mM Tris-Cl pH 6.8), heated to 95 $^{\circ}$ C for 10 min, then 15–25 μ L of lysate was loaded into 4–15% TGX gels (Bio-Rad Laboratories, Hercules, CA, USA) and separated via SDS-PAGE. After separation, samples were transferred to PVDF membranes (Merck Millipore), with the exception of samples that required probing for murine phosphorylated MLKL, which were transferred to nitrocellulose membranes (Cytiva, Marlborough, MA, USA). After transfer, membranes were

blocked with 5% w/v skim milk powder in PBS-T (0.1% v/v Tween-20), then incubated overnight at +4 °C in the relevant primary antibody in PBS-T with 2% w/v BSA and 0.02% w/v sodium azide. The following day, membranes were washed, then incubated in the relevant secondary antibody diluted in 5% skim milk in PBS-T for approximately 1 h at room temperature. Membranes were washed again, then visualised on a ChemiDoc™ Gel Imaging System (Bio-Rad Laboratories) using Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore). Concentrations of various antibodies are listed above. All full, uncropped Western blots from this study are included as Supplemental Material.

Cellular Thermal Shift Assay (CETSA)

MDF and U937 cells were seeded to achieve 1.5×10^6 cells per temperature point. After treatment with AMG-47a at 10 μ M, GSK-481, GSK-872 or Nec-1s at 20 μ M, or an equivalent amount of DMSO, cells were incubated for 1 h at 37 °C, then pelleted, washed, and resuspended in 650 μ L DPBS (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) containing cComplete™ EDTA-free Protease Inhibitor Cocktail (Roche, Basel, Switzerland). For each temperature point as indicated below, 100 μ L of these live cell suspensions were heated for 3 min in a T100 Thermal Cycler (Bio-Rad), cooled at room temperature for 3 min, snap frozen in liquid N₂ and stored at -80 °C overnight. After a single freeze-thaw, soluble and precipitated protein were separated by centrifugation at 17,000 \times g for 30 min at 4 °C, and the soluble protein fractions were resolved by SDS-PAGE and analysed by Western Blot, as described above, with the exception that proteins were transferred to a nitrocellulose membrane using the iBlot Dry Blotting System (Invitrogen, Thermo Fisher Scientific).

Temperature gradients were optimised for each cell line and each protein of interest. For U937, the temperature gradients (°C) used for each human protein were: RIPK1 (44.0, 44.7, 45.9, 47.9, 50.2, 51.9), RIPK3 (44.7, 45.9, 47.9, 50.2, 51.9, 53.2), and MLKL (46.6, 47.7, 49.5, 51.6, 53.2, 54.3). For MDF, the temperature gradients (°C) used for each mouse protein were RIPK1 (43.9, 45.9, 48.2, 49.9, 51.2, 52.0), RIPK3 (48.9, 50.9, 53.2, 55.0, 56.2, 57.0), and MLKL (45.3, 47.2, 49.4, 51.0, 52.2, 53.0).

In vitro kinase binding assay

Binding of AMG-47a to RIPK1, RIPK3 and MLKL was assessed using the KINOMEScan® Assay Platform (Eurofins DiscoverX, Fremont, CA, USA [68]). In brief, AMG-47a binding to each target was assessed using a competitive binding assay with a compound dilution series with a maximum concentration of 12 μ M. Binding of AMG-47a to VEGFR-2, previously described as an interactor [57], was also assessed as a positive control at two discrete concentrations: 50 nM and 500 nM.

RIPK3 and RIPK1 kinase activity assays

Recombinant wild-type human RIPK3⁽²⁻³¹¹⁾ and RIPK1⁽²⁻³⁷²⁾ were expressed in Sf21 insect cells as TEV protease-cleavable N-terminal His₆ fusions and purified as previously described [3]. The kinase activity assay was conducted in 384-well plates using the ADP-Glo™ Kinase Assay (Promega). In brief, a 10-point 3-fold dilution series of AMG-47a was prepared (maximum concentration 50 or 100 μ M for RIPK1 and RIPK3, respectively) and combined with either 10 nM human RIPK3⁽²⁻³¹¹⁾ or 200 nM human RIPK1⁽²⁻³⁷²⁾ and 10 μ M ATP in a protein-specific buffer (RIPK3 buffer: 50 mM NaCl, 50 mM HEPES, pH 7.4, 30 mM MgCl₂, 0.05% w/v BSA, 0.01% v/v Tween-20, 1 mM DTT; RIPK1 buffer: 50 mM NaCl, 50 mM TRIS, pH 7.4, 30 mM MgCl₂, 0.05% w/v BSA, 0.01% v/v Triton-X, 1 mM DTT). After a 4 h incubation at room temperature the reaction was stopped with ADP-Glo reagent, then incubated for a further 40–60 min. Kinase Detection Reagent was then added, and the reaction was incubated at room temperature for a further 30–60 min. Luminescence was measured using an Envision plate reader (Perkin Elmer), and raw luminescence data were normalised to DMSO (0% inhibition) and either 1 μ M GSK-872 (for RIPK3; 100% inhibition) or 1 μ M GSK-481 (for RIPK1; 100% inhibition).

Inducible RIPK3 cell death assays

A cDNA encoding wild-type human RIPK3 was cloned into the doxycycline-inducible pF TRE 3 G PGK puro expression vector as previously described [25], and introduced into wild-type, *MLKL*^{-/-} and *RIPK1*^{-/-} U937 cells using lentiviral transduction as previously described [30]. Optimisation experiments were performed in 24- and 96-well plates, with U937 cells seeded at 1×10^5 and 2×10^4 cells/well respectively in the presence of 20 nM doxycycline to induce expression. Cells were treated with IDN-6556, NSA,

Nec-1s, GSK-481, GSK-872, GSK-843, or an equivalent amount of DMSO, as indicated in figure legends. After 24 h, cells were harvested, and death analysed by PI uptake using flow cytometry.

Analysis of the ability of AMG-47a to block cell death caused by induction of human RIPK3 was performed in 384-well plates, seeding at 2000 cells/well. A 10-point, 3-fold dilution series of AMG-47a was prepared (maximum end concentration 36 μ M), and cells were preincubated with AMG-47a or DMSO, with 5 μ M of IDN-6556. After 2 h, expression of the transgene was induced by addition of 40 nM doxycycline to induce cell death. Cells were incubated for 48 h at 37 °C, after which cell viability was assessed using the CellTiter-Glo® 2.0 Cell Viability Assay (Promega) as per the manufacturer's instructions, with luminescence data collected using an Envision plate reader (Perkin Elmer, Waltham, MA, USA).

IncuCyte cell death assay

U937 cells were seeded at 3×10^4 cells/well into 48-well plates in RPMI with 8% FCS and left to settle overnight; *MLKL*^{-/-} cells with inducible *MLKL*⁽¹⁻¹⁸⁰⁾-gyrase were incubated overnight with 20 ng/ml doxycycline, either in the presence or absence of 1 μ M necrosulfonamide (NSA). Just prior to transfer to the IncuCyte instrument, cells expressing *MLKL*⁽¹⁻¹⁸⁰⁾-gyrase were treated with 700 nM coumermycin to induce dimerisation and, in conjunction, wild-type U937 were treated with TNF (100 ng/ml), the Smac-mimetic Compound A (500 nM) and the pan-caspase inhibitor IDN-6556 (5 μ M) to induce necroptosis, TNF and Smac-mimetic alone to induce necroptosis, or left untreated. Finally, all cells were treated with 1 μ g/ml propidium iodide and moved into the Incu-Cyte S3 System (Essen Bioscience) and imaged initially after 15 min (to allow the cells to settle), then every 30 min thereafter, on a $\times 20$ objective using default bright-field and red channel settings, with three distinct fields obtained per well. At the conclusion of the experiment, micrographs were examined using ImageJ v.1.53n [93] in a blinded manner for morphological signs of either necroptosis or apoptosis over time.

Data collection and analysis

Flow cytometry data were collected using a BD FACSCalibur™ analyser (BD Biosciences, Franklin Lakes, NJ, USA) and analysed using FlowJo™ for Mac v10.6 (Becton Dickinson and Company, Franklin Lakes, NJ, USA). For all experiments, data was plotted using GraphPad Prism8 (GraphPad Software, San Diego, CA, USA) and has been displayed as individual data points with the mean.

All statistics were generated in GraphPad Prism8. Where K_d or IC_{50} were determined (cell death assays, kinase binding assays, kinase activity assays), the best fit curve was generated using an inhibitor vs response (three parameters) model of linear regression. K_d/IC_{50} values reported were generated from these analyses. For analysis of MDF cell death assays, we used a standard paired *t*-test. For NTD-gyrase experiments comparing different genotypes we used one-way ANOVA, followed by Dunnett's multiple comparison test. For the NTD-gyrase experiments comparing the effects of different drugs in the same genotype, we performed repeated measures (randomised block) ANOVA, followed by Dunnett's multiple comparison test. Where there were missing data, a mixed model method comparable to repeated measures ANOVA was used instead, which, in the absence of missing values, gives the same *P* values and multiple comparisons tests as repeated measures ANOVA, and can be interpreted comparably to this analysis where data are incomplete.

DATA AVAILABILITY

All primary data are available from the corresponding authors upon request.

REFERENCES

- Guo H, Omoto S, Harris Philip A, Finger Joshua N, Bertin J, Gough Peter J, et al. Herpes simplex virus suppresses necroptosis in human cells. *Cell Host Microbe*. 2015;17:243–51.
- Liu X, Li Y, Peng S, Yu X, Li W, Shi F, et al. Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1/3 ubiquitination. *Cell Death Dis*. 2018;9:53.
- Petrie EJ, Sandow JJ, Lehmann WIL, Liang L-Y, Coursier D, Young SN, et al. Viral MLKL homologs subvert necroptotic cell death by sequestering cellular RIPK3. *Cell Rep*. 2019;28:3309–19.
- Upton JW, Kaiser WJ, Mocarski ES. Virus inhibition of RIP3-dependent necrosis. *Cell Host Microbe*. 2010;7:302–13.

5. Pearson JS, Gogha C, Mühlen S, Nachbur U, Pham CLL, Zhang Y, et al. EsP1 is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation. *Nat Microbiol*. 2017;2:16258.
6. Khoury MK, Gupta K, Franco SR, Liu B. Necroptosis in the pathophysiology of disease. *Am J Pathol*. 2020;190:272–85.
7. Tovey Crutchfield EC, Garnish SE, Hildebrand JM. The Role of the key effector of necroptotic cell death, MLKL, in mouse models of disease. *Biomolecules*. 2021;11:803.
8. Zhu F, Zhang W, Yang T, He S-D. Complex roles of necroptosis in cancer. *J Zhejiang Univ Sci B*. 2019;20:399–413.
9. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. *Nat Chem Biol*. 2005;1:112–9.
10. Kalai M, Van Loo G, Vanden Berghe T, Meeus A, Burm W, Saelens X, et al. Tipping the balance between necrosis and apoptosis in human and murine cells treated with interferon and dsRNA. *Cell Death Differ*. 2002;9:981–94.
11. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. *Nat Immunol*. 2000;1:489–95.
12. He S, Liang Y, Shao F, Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. *Proc Natl Acad Sci*. 2011;108:20054.
13. Robinson N, McComb S, Mulligan R, Dudani R, Krishnan L, Sad S. Type I interferon induces necroptosis in macrophages during infection with *Salmonella enterica* serovar Typhimurium. *Nat Immunol*. 2012;13:954–62.
14. He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF- α . *Cell*. 2009;137:1100–11.
15. Feoktistova M, Geserick P, Kellert B, Dimitrova Diana P, Langlais C, Hupe M, et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. *Mol Cell*. 2011;43:449–63.
16. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. *Mol Cell*. 2011;43:432–48.
17. Feltham R, Silke J. The small molecule that packs a punch: ubiquitin-mediated regulation of RIPK1/FADD/caspase-8 complexes. *Cell Death Differ*. 2017;24:1196–204.
18. Cho Y, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. *Cell*. 2009;137:1112–23.
19. Sun X, Yin J, Starovasnik MA, Fairbrother WJ, Dixit VM. Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. *J Biol Chem*. 2002;277:9505–11.
20. Zhang X, Dowling JP, Zhang J. RIPK1 can mediate apoptosis in addition to necroptosis during embryonic development. *Cell Death Dis*. 2019;10:245.
21. Newton K, Wickliffe KE, Dugger DL, Maltzman A, Roose-Girma M, Dohse M, et al. Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis. *Nature*. 2019;574:428–31.
22. Lalaoui N, Boyden SE, Oda H, Wood GM, Stone DL, Chau D, et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. *Nature*. 2020;577:103–8.
23. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed Lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. *Cell*. 2012;148:213–27.
24. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. *Proc Natl Acad Sci*. 2012;109:5322.
25. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang J-G, Alvarez-Diaz S, et al. The Pseudokinase MLKL Mediates necroptosis via a molecular switch mechanism. *Immunity*. 2013;39:443–53.
26. Hildebrand JM, Tanzer MC, Lucet IS, Young SN, Spall SK, Sharma P, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. *Proc Natl Acad Sci*. 2014;111:15072.
27. Cai Z, Jitkaew S, Zhao J, Chiang H-C, Choksi S, Liu J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. *Nat Cell Biol*. 2014;16:55–65.
28. Chen X, Li W, Ren J, Huang D, He W-T, Song Y, et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. *Cell Res*. 2014;24:105–21.
29. Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I, et al. MLKL Compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. *Cell Rep*. 2014;7:971–81.
30. Tanzer MC, Matti I, Hildebrand JM, Young SN, Wardak A, Tripaydonis A, et al. Evolutionary divergence of the necroptosis effector MLKL. *Cell Death Differ*. 2016;23:1185–97.
31. Petrie EJ, Sandow JJ, Jacobsen AV, Smith BJ, Griffin MDW, Lucet IS, et al. Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis. *Nat Commun*. 2018;9:2422.
32. Samson AL, Zhang Y, Geoghegan ND, Gavin XJ, Davies KA, Mlodzianowski MJ, et al. MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. *Nat Commun*. 2020;11:3151.
33. Davies KA, Tanzer MC, Griffin MDW, Mok YF, Young SN, Qin R, et al. The brace helices of MLKL mediate interdomain communication and oligomerisation to regulate cell death by necroptosis. *Cell Death Differ*. 2018;25:1567–80.
34. Wang H, Sun L, Su L, Rizo J, Liu L, Wang L-F, et al. Mixed lineage kinase domain-like protein mlkl causes necrotic membrane disruption upon phosphorylation by RIP3. *Mol Cell*. 2014;54:133–46.
35. Garnish SE, Meng Y, Koide A, Sandow JJ, Denbaum E, Jacobsen AV, et al. Conformational interconversion of MLKL and disengagement from RIPK3 precede cell death by necroptosis. *Nat Commun*. 2021;12:2211.
36. Meng Y, Davies KA, Fitzgibbon C, Young SN, Garnish SE, Horne CR, et al. Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosis. *Nat Commun*. 2021;12:6783.
37. Li D, Xu T, Cao Y, Wang H, Li L, Chen S, et al. A cytosolic heat shock protein 90 and cochaperone CDC37 complex is required for RIP3 activation during necroptosis. *Proc Natl Acad Sci*. 2015;112:5017.
38. Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L, et al. Disruption of Hsp90 Function Results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor- κ B activation. *J Biol Chem*. 2000;275:10519–26.
39. Jacobsen AV, Lowes KN, Tanzer MC, Lucet IS, Hildebrand JM, Petrie EJ, et al. HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. *Cell Death Dis*. 2016;7:e2051.
40. Moquin DM, McQuade T, Chan FK-M. CYLD deubiquitinates RIP1 in the TNF α -induced necrosome to facilitate kinase activation and programmed necrosis. *PLOS ONE*. 2013;8:e76841.
41. de Almagro MC, Goncharov T, Newton K, Vucic D. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination. *Cell Death Dis*. 2015;6:e1800.
42. Onizawa M, Oshima S, Schulze-Topphoff U, Osés-Prieto JA, Lu T, Tavares R, et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. *Nat Immunol*. 2015;16:618–27.
43. Wang H, Meng H, Li X, Zhu K, Dong K, Mookhtiar AK, et al. PELL1 functions as a dual modulator of necroptosis and apoptosis by regulating ubiquitination of RIPK1 and mRNA levels of c-FLIP. *Proc Natl Acad Sci*. 2017;114:11944.
44. Choi S-W, Park H-H, Kim S, Chung JM, Noh H-J, Kim SK, et al. PELL1 Selectively targets kinase-active RIP3 for ubiquitylation-dependent proteasomal degradation. *Mol Cell*. 2018;70:920–35.
45. McNamara DE, Dovey CM, Hale AT, Quarato G, Grace CR, Guibao CD, et al. Direct activation of human MLKL by a select repertoire of inositol phosphate metabolites. *Cell Chem Biol*. 2019;26:863–77.
46. Dovey CM, Diep J, Clarke BP, Hale AT, McNamara DE, Guo H, et al. MLKL requires the inositol phosphate code to execute necroptosis. *Mol Cell*. 2018;70:936–48.
47. Quarato G, Guy Cliff S, Grace Christy R, Llambi F, Nourse A, Rodriguez Diego A, et al. Sequential engagement of distinct mlk1 phosphatidylinositol-binding sites executes necroptosis. *Mol Cell*. 2016;61:589–601.
48. Gong Y-N, Guy C, Olason H, Becker JU, Yang M, Fitzgerald P, et al. ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. *Cell*. 2017;169:286–300.
49. Yoon S, Kovalenko A, Bogdanov K, Wallach D. MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. *Immunity*. 2017;47:51–65.
50. Ousingasawat J, Cabrita I, Wanitchakool P, Sirianant L, Krautwald S, Linkermann A, et al. Ca²⁺ signals, cell membrane disintegration, and activation of TMEM16F during necroptosis. *Cell Mol Life Sci*. 2017;74:173–81.
51. Fan W, Guo J, Gao B, Zhang W, Ling L, Xu T, et al. Flotillin-mediated endocytosis and ALIX-syntenin-1-mediated exocytosis protect the cell membrane from damage caused by necroptosis. *Sci Signal*. 2019;12:eaaw3423.
52. Samson AL, Garnish SE, Hildebrand JM, Murphy JM. Location, location, location: a compartmentalized view of necroptotic signaling. *Sci Signal*. 2021;14:eabc6178.
53. Chen W, Zhou Z, Li L, Zhong C-Q, Zheng X, Wu X, et al. Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like (mlkl) interaction in necroptotic signaling. *J Biol Chem*. 2013;288:16247–61.
54. Davies KA, Fitzgibbon C, Young SN, Garnish SE, Yeung W, Coursier D, et al. Distinct pseudokinase domain conformations underlie divergent activation mechanisms among vertebrate MLKL orthologues. *Nat Commun*. 2020;11:3060.
55. Zhao XM, Chen Z, Zhao JB, Zhang PP, Pu YF, Jiang SH, et al. Hsp90 modulates the stability of MLKL and is required for TNF-induced necroptosis. *Cell Death Dis*. 2016;7:e2089.
56. Bigenzahn JW, Fauster A, Rebsamen M, Kandasamy RK, Scorzoni S, Vladimer GI, et al. An inducible retroviral expression system for tandem affinity purification mass-spectrometry-based proteomics identifies mixed lineage kinase domain-

- like protein (MLKL) as an heat shock protein 90 (HSP90) client. *Mol & Cell Proteom.* 2016;15:1139.
57. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, et al. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, sar, and in vivo anti-inflammatory activity. *J Medicinal Chem.* 2006;49:5671–86.
 58. Brumatti G, Ma C, Lalaoui N, Nguyen N-Y, Navarro M, Tanzer MC, et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. *Sci Transl Med.* 2016;8:339ra69.
 59. Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen N-YN, Vasilikos L, et al. Targeting p38 or MK2 enhances the anti-leukemic activity of smac-mimetics. *Cancer Cell.* 2016;29:145–58.
 60. Petrie EJ, Czabotar PE, Murphy JM. The structural basis of necroptotic cell death signaling. *Trends Biochem Sci.* 2019;44:53–63.
 61. Murphy JM. The Killer Pseudokinase Mixed Lineage Kinase Domain-Like Protein (MLKL). *Cold Spring Harbor Perspectives in Biology.* 2020;12:a036376.
 62. Cook WD, Moujalled DM, Ralph TJ, Lock P, Young SN, Murphy JM, et al. RIPK1 and RIPK3-induced cell death mode is determined by target availability. *Cell Death Differ.* 2014;21:1600–12.
 63. Mandal P, Berger Scott B, Pillay S, Moriwaki K, Huang C, Guo H, et al. RIP3 induces apoptosis independent of pro necrotic kinase activity. *Mol Cell.* 2014;56:481–95.
 64. Sun X, Lee J, Navas T, Baldwin DT, Stewart TA, Dixit VM. RIP3, a novel apoptosis-inducing kinase. *J Biol Chem.* 1999;274:16871–5.
 65. Hildebrand JM, Kauppi M, Majewski IJ, Liu Z, Cox AJ, Miyake S, et al. A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. *Nat Commun.* 2020;11:3150.
 66. Liu Z, Dagle LF, Shield-Artin K, Young SN, Bankovacki A, Wang X, et al. Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis. *EMBO J.* 2021;40:e103718.
 67. Molina DM, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. *Science.* 2013;341:84–87.
 68. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. *Nat Biotechnol.* 2005;23:329–36.
 69. Muise-Helmericks RC, Rosen N. Identification of a novel repressive element in the proximal Ick promoter. *J Biol Chem.* 1995;270:27538–43.
 70. Hirsch CL, Smith-Windsor EL, Bonham K. Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells. *Int J Cancer.* 2006;118:547–54.
 71. Morris SM, Mhyre AJ, Carmack SS, Myers CH, Burns C, Ye W, et al. A modified gene trap approach for improved high-throughput cancer drug discovery. *Oncogene.* 2018;37:4226–38.
 72. Sethi A, Horne CR, Fitzgibbon C, Wilde K, Davies KA, Garnish SE, et al. Membrane permeabilization is mediated by distinct epitopes in mouse and human orthologs of the necroptosis effector, MLKL. *Cell Death Differ.* 2022; <https://doi.org/10.1038/s41418-022-00965-6>.
 73. Conos SA, Chen KW, De Nardo D, Hara H, Whitehead L, Nunez G, et al. Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. *Proc Natl Acad Sci USA.* 2017;114:E961–E969.
 74. Newton K, Wickliffe KE, Maltzman A, Dugger DL, Strasser A, Pham VC, et al. RIPK1 inhibits ZBP1-driven necroptosis during development. *Nature.* 2016;540:129–33.
 75. Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T, et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. *Cell.* 2014;157:1175–88.
 76. Kaiser WJ, Daley-Bauer LP, Thapa RJ, Mandal P, Berger SB, Huang C, et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. *Proc Natl Acad Sci.* 2014;111:7753–8.
 77. Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. *Cell.* 2014;157:1189–202.
 78. Moujalled DM, Cook WD, Okamoto T, Murphy J, Lawlor KE, Vince JE, et al. TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1. *Cell Death Dis.* 2013;4:e465.
 79. Kearney CJ, Cullen SP, Clancy D, Martin SJ. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis. *FEBS J.* 2014;281:4921–34.
 80. Wang L, Chang X, Feng J, Yu J, Chen G. TRADD Mediates RIPK1-Independent Necroptosis Induced by Tumor Necrosis Factor. *Frontiers in Cell and Developmental Biology* 2020;7:393.
 81. Ingram JP, Thapa RJ, Fisher A, Tummers B, Zhang T, Yin C, et al. ZBP1/DAI drives RIPK3-mediated cell death induced by IFNs in the absence of RIPK1. *J Immunol.* 2019;203:1348–55.
 82. Yang D, Liang Y, Zhao S, Ding Y, Zhuang Q, Shi Q, et al. ZBP1 mediates interferon-induced necroptosis. *Cell Mol Immunol.* 2020;17:356–68.
 83. Zhuang C, Chen F. Small-molecule inhibitors of necroptosis: current status and perspectives. *J Med. Chem.* 2020;63:1490–510.
 84. Samson AL, Fitzgibbon C, Patel KM, Hildebrand JM, Whitehead LW, Rimes JS, et al. A toolbox for imaging RIPK1, RIPK3, and MLKL in mouse and human cells. *Cell Death Differ.* 2021;28:2126–44.
 85. Vince JE, Wong WW-L, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNF α -dependent apoptosis. *Cell.* 2007;131:682–93.
 86. Bossen C, Ingold K, Tardivel A, Bodmer J-L, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. *J Biol Chem.* 2006;281:13964–71.
 87. Tanzer MC, Khan N, Rickard JA, Etemadi N, Lalaoui N, Spall SK, et al. Combination of IAP antagonist and IFN γ activates novel caspase-10- and RIPK1-dependent cell death pathways. *Cell Death Differ.* 2017;24:481–91.
 88. Alvarez-Diaz S, Dillon CP, Lalaoui N, Tanzer MC, Rodriguez DA, Lin A, et al. The pseudokinase MLKL and the Kinase RIPK3 have distinct roles in autoimmune disease caused by loss of death-receptor-induced apoptosis. *Immunity.* 2016;45:513–26.
 89. Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF- κ B signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. *Mol Cell Biol.* 2004;24:1464–9.
 90. Li MX, Tan IKL, Ma SB, Hockings C, Kratina T, Dengler MA, et al. BAK α 6 permits activation by BH3-only proteins and homooligomerization via the canonical hydrophobic groove. *Proc Natl Acad Sci.* 2017;114:7629.
 91. Chin HS, Li MX, Tan IKL, Ninnis RL, Reljic B, Scicluna K, et al. VDAC2 enables BAX to mediate apoptosis and limit tumor development. *Nat Commun.* 2018;9:4976.
 92. Jaco I, Annibaldi A, Lalaoui N, Wilson R, Tenev T, Laurin L, et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. *Mol Cell.* 2017;66:698–710.
 93. Schneider CA, Rasband WS, Eliceiri KW. NIH image to imageJ: 25 years of image analysis. *Nat Methods.* 2012;9:671–5.

ACKNOWLEDGEMENTS

We thank the following people for technical assistance: Sam Young (cloning), Anne Hempel (CETSA), and Wil Lehmann (Western blots). Thanks also to Vishva Dixit for *Ripk3*^{-/-} mice, Grant Dewson for supplying *Bax*^{-/-}*Bak*^{-/-} and wild-type MEFs, and Jean-Marc Garnier for coordinating DiscoverX analyses. We acknowledge Compounds Australia (www.compoundsaustralia.com) for their provision of specialised compound management and logistics services to the project.

AUTHOR CONTRIBUTIONS

AVJ designed and performed experiments, analyzed data and co-wrote the paper with JS and JMM; CLP, KNL, AEA, YZ, NE, CF, WJAK, ALS and MFvD performed experiments and analyzed data; DCSH, HJS, GL, JS and JMM supervised the project and contributed to experimental design and data analysis. All authors commented on the manuscript.

FUNDING

This work was funded by Australian National Health and Medical Research Council (NHMRC) grants (1046984, 1067289, 1105023, 1124735, 1124737 and 2002965) and fellowships (JMM: 1105754, 1172929; JS: 1058190,1107149; GL: 1117089; DCSH: 1156024); Anaxis Pharma Pty Ltd for funding support; and was made possible through Victorian State Government Operational Infrastructure Support, NHMRC IRIISS grant (9000719) and Australian Cancer Research Foundation funding. AVJ and CLP were supported by an Australian Government Research Training Program Stipend Scholarship. WEHI's screening facility is supported by Therapeutic Innovation Australia (TIA). TIA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program.

COMPETING INTERESTS

CLP, KNL, AEA, YZ, NE, CF, WJAK, ALS, HJS, GL, JS and JMM contribute, or have contributed, to a project developing necroptosis inhibitors in collaboration with Anaxis Pty Ltd. AVJ, MFvD, and DCSH declare no conflicts of interest.

ETHICS STATEMENT

Mouse dermal fibroblasts were prepared using procedures approved by and conducted in accordance with the Animal Ethics Committee of the Walter and Eliza Hall Institute, Australia.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41419-022-04740-w>.

Correspondence and requests for materials should be addressed to John Silke or James M. Murphy.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022